Figures
Developing New Drug Treatments for Tuberculosis.
This month's cover image, showing the treatment regimen of a patient coinfected with multi-drug resistant TB (MDR-TB) and HIV, links to a collection of three PLoS Medicine Policy Forum articles arising from the Médecins Sans Frontières Symposium "No Time to Wait: Overcoming the Gaps in TB Drug Development." For the first time in decades there is a TB drug pipeline, but the paucity of candidates is still cause for alarm (see Casenghi et al. e293). The long duration of current TB regimens, the high prevalence of HIV co-infection, and the emergence of drug-resistant TB underscore the need for new TB drugs, say Schluger et al. (e302) in their article on building TB clinical trials capacity in high-burden countries. The expansion of MDR-TB treatment programs provides the setting in which MDR-TB trials can be implemented, say Mitnick et al. (e292).
Image Credit: Image by Brendan Bannon (http://www.brendanbannon.com/
Citation: (2007) PLoS Medicine Issue Image | Vol. 4(11) November 2007. PLoS Med 4(11): ev04.i11. https://doi.org/10.1371/image.pmed.v04.i11
Published: November 27, 2007
Copyright: © 2007 Brendan Bannon. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This month's cover image, showing the treatment regimen of a patient coinfected with multi-drug resistant TB (MDR-TB) and HIV, links to a collection of three PLoS Medicine Policy Forum articles arising from the Médecins Sans Frontières Symposium "No Time to Wait: Overcoming the Gaps in TB Drug Development." For the first time in decades there is a TB drug pipeline, but the paucity of candidates is still cause for alarm (see Casenghi et al. e293). The long duration of current TB regimens, the high prevalence of HIV co-infection, and the emergence of drug-resistant TB underscore the need for new TB drugs, say Schluger et al. (e302) in their article on building TB clinical trials capacity in high-burden countries. The expansion of MDR-TB treatment programs provides the setting in which MDR-TB trials can be implemented, say Mitnick et al. (e292).
Image Credit: Image by Brendan Bannon (http://www.brendanbannon.com/